KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex

The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Donald D., Luo, Xiuquan, Wang, Zhaohui, Jay, Christopher M., Brunicardi, Francis C., Maltese, William, Manning, Luisa, Senzer, Neil, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979018/
https://www.ncbi.nlm.nih.gov/pubmed/29851957
http://dx.doi.org/10.1371/journal.pone.0193644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979018/
https://www.ncbi.nlm.nih.gov/pubmed/29851957
http://dx.doi.org/10.1371/journal.pone.0193644

Ejemplares similares